Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Amplified”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00482391
What this trial is testing

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 95
Early research (Phase 1)Study completedNCT00911898
What this trial is testing

MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers

Who this might be right for
Her2 Amplified Solid TumorsMetastatic Breast Cancer
Merrimack Pharmaceuticals 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT06413745
What this trial is testing

Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

Who this might be right for
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd. 59
Testing effectiveness (Phase 2)Study completedNCT04596150
What this trial is testing

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Who this might be right for
NeoplasmsBreast NeoplasmsBreast Neoplasms, Triple-Negative+2 more
CytomX Therapeutics 125
Testing effectiveness (Phase 2)UnknownNCT03412383
What this trial is testing

Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Who this might be right for
Breast CancerHER2 Gene Mutation
Peking Union Medical College 14
Testing effectiveness (Phase 2)Study completedNCT03365882
What this trial is testing

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Who this might be right for
Colon AdenocarcinomaERBB2 Gene AmplificationRectal Adenocarcinoma+16 more
SWOG Cancer Research Network 240
Testing effectiveness (Phase 2)Study completedNCT00258349
What this trial is testing

Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer

Who this might be right for
Breast CancerMale Breast CancerRecurrent Breast Cancer+3 more
National Cancer Institute (NCI) 16
Large-scale testing (Phase 3)Study completedNCT00281658
What this trial is testing

Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 444
Testing effectiveness (Phase 2)Ended earlyNCT00820924
What this trial is testing

Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 23
Testing effectiveness (Phase 2)Study completedNCT01050322
What this trial is testing

Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment.

Who this might be right for
BRMS1Performance Status Zero to Two for Beginning the StudyPatient With a Maximum of One Chemotherapy+1 more
Latin American Cooperative Oncology Group 142
Large-scale testing (Phase 3)Study completedNCT00878709
What this trial is testing

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Who this might be right for
Breast Cancer
Puma Biotechnology, Inc. 2,840
Early research (Phase 1)Study completedNCT00031681
What this trial is testing

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Who this might be right for
Advanced Adult Primary Liver CancerCarcinoma of the AppendixEstrogen Receptor-negative Breast Cancer+85 more
National Cancer Institute (NCI) 41